Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIK665 in Refractory or Relapsed Lymphoma or Multiple Myeloma
NCT02992483Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of S64315 in lymphoma and multiple myeloma (MM), sponsored by Novartis. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 2 years, Incidence of Dose Limiting Toxicities at 2 years and 3 more. Started Jul 2017; status: completed.
02
Drugs
S64315
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02992483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992483.